Cardio-facio-cutaneous Syndrome with Severe Inflammatory Cutaneous Lesions: Dramatic Effect of Dupilumab

Acta Derm Venereol. 2024 Sep 5:104:adv40465. doi: 10.2340/actadv.v104.40465.

Authors

Sara A Altandi¹, Pol A Apoil², Juliette Mazereeuw-Hautier³, Maella Severino-Freire¹

Affiliations

¹ Department of Dermatology, Reference Center for Rare Skin Diseases, Toulouse, France.
² Institut Fédératif de Biologie (IFB) Paul Sabatier University, Toulouse, France.
³ Department of Dermatology, Reference Center for Rare Skin Diseases, Toulouse, France. mazereeuw-hautier.j@chu-toulouse.fr.

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Ectodermal Dysplasia / drug therapy
Facies
Failure to Thrive
Female
Heart Defects, Congenital / complications
Heart Defects, Congenital / drug therapy
Heart Diseases / drug therapy
Humans
Male
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
dupilumab

Supplementary concepts

Cardiofaciocutaneous syndrome